Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Aeglea Bio Therapeutics Inc    AGLE

AEGLEA BIO THERAPEUTICS INC (AGLE)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/09/2018 10/10/2018 10/11/2018 10/12/2018 10/15/2018 Date
9.51(c) 8.84(c) 9.07(c) 9.08(c) 9.41(c) Last
124 653 175 621 180 198 211 674 207 304 Volume
-1.35% -7.05% +2.60% +0.11% +3.63% Change
More quotes
Financials (USD)
Sales 2018 5,43 M
EBIT 2018 -37,1 M
Net income 2018 -36,3 M
Finance 2018 39,6 M
Yield 2018 -
Sales 2019 2,03 M
EBIT 2019 -44,1 M
Net income 2019 -49,0 M
Finance 2019 74,0 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 29,6x
EV / Sales2019 62,4x
Capitalization 201 M
More Financials
Company
Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer.It develops pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1... 
Sector
Biotechnology & Medical Research
Calendar
10/17 | 02:30pmPresentation
More about the company
Surperformance© ratings of Aeglea Bio Therapeutics In
Trading Rating : Investor Rating :
More Ratings
Latest news on AEGLEA BIO THERAPEUTICS IN
10/10AEGLEA BIOTHERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holde..
AQ
10/10Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data i..
GL
10/01AEGLEA BIO THERAPEUTICS : FDA Grants Rare Pediatric Disease Designation to Pegzi..
AQ
09/17Aeglea BioTherapeutics Announces Oral Presentation of Preclinical Data on New..
GL
09/05AEGLEA BIO THERAPEUTICS : BioTherapeutics Announces Positive Interim Clinical Da..
AQ
09/04AEGLEA BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements an..
AQ
09/04Aeglea BioTherapeutics Announces Positive Interim Clinical Data and Completio..
GL
08/28Aeglea BioTherapeutics to Present at 2018 Wells Fargo Healthcare Conference
GL
08/28AEGLEA BIO THERAPEUTICS : BioTherapeutics to Present New Interim Phase 1/2 Clini..
AQ
08/27Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data i..
GL
More news
Sector news : Bio Therapeutic Drugs
07:30aSanofi's Dupixent Shows Positive Headline Results in Two Phase 3 Studies
DJ
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
10/02GILEAD SCIENCES : Allogene Sets IPO at 16 Million Shares; Sees Pricing $16-$18
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/14The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Resul.. 
10/12Key events next week - healthcare
1
10/10Zacks Investment Research Upgrades Aeglea Bio Therapeutics $AGLE to Hold  
10/10TREND REVERSAL DOWN ALERT: $AGLE AEGLEA BIOTHERAPEUTICS ? TradeIdeas via  
10/10Get the latest news and updates for $VITC $ABIL $AGLE $CDNA $DECK automatical..
1
More tweets
Qtime:12
News from SeekingAlpha
10/12Key events next week - healthcare 
10/01FDA grants Rare Pediatric Disease designation to Pegzilarginase for Arginase .. 
09/21After Hours Gainers / Losers (09/21/2018) 
09/07YOUR DAILY SCOOP : Recro Proceeds, MannKind Zooms, Aduro's Publication 
09/05Aeglea BioTherapeutics (AGLE) Investor Presentation - Slideshow 
Chart AEGLEA BIO THERAPEUTICS INC
Duration : Period :
Aeglea Bio Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AEGLEA BIO THERAPEUTICS IN
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 19,0 $
Spread / Average Target 102%
EPS Revisions
Managers
NameTitle
Anthony G. Quinn President, Chief Executive Officer & Director
Armen B. Shanafelt Chairman
Charles N. York Chief Financial Officer & Vice President
James Wooldridge Chief Medical Officer
George Georgiou Director
Sector and Competitors
1st jan.Capitalization (M$)
AEGLEA BIO THERAPEUTICS INC73.94%201
GILEAD SCIENCES1.59%93 985
VERTEX PHARMACEUTICALS18.54%44 892
REGENERON PHARMACEUTICALS0.42%39 451
NEUROCRINE BIOSCIENCES, INC.41.84%9 776
GENMAB-10.38%8 786